263 related articles for article (PubMed ID: 29361432)
21. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly.
Kuhn-Thiel AM; Weiß C; Wehling M;
Drugs Aging; 2014 Feb; 31(2):131-40. PubMed ID: 24353033
[TBL] [Abstract][Full Text] [Related]
22. [Management of polypharmacy in older people with multimorbidity].
Hoffmann U
Inn Med (Heidelb); 2024 Jan; 65(1):9-16. PubMed ID: 38059997
[TBL] [Abstract][Full Text] [Related]
23. Deprescribing in older people approaching end-of-life: development and validation of STOPPFrail version 2.
Curtin D; Gallagher P; O'Mahony D
Age Ageing; 2021 Feb; 50(2):465-471. PubMed ID: 32997135
[TBL] [Abstract][Full Text] [Related]
24. Optimising pharmacotherapy in older cancer patients with polypharmacy.
Vrijkorte E; de Vries J; Schaafsma R; Wymenga M; Oude Munnink T
Eur J Cancer Care (Engl); 2020 Jan; 29(1):e13185. PubMed ID: 31692151
[TBL] [Abstract][Full Text] [Related]
25. GPs' mindlines on deprescribing antihypertensives in older patients with multimorbidity: a qualitative study in English general practice.
Kuberska K; Scheibl F; Sinnott C; Sheppard JP; Lown M; Williams M; Payne RA; Mant J; McManus RJ; Burt J
Br J Gen Pract; 2021 Jul; 71(708):e498-e507. PubMed ID: 34001537
[TBL] [Abstract][Full Text] [Related]
26. Geriatric Polypharmacy: Two Physicians' Personal Perspectives.
Chen Z; Buonanno A
Clin Geriatr Med; 2017 May; 33(2):283-288. PubMed ID: 28364996
[TBL] [Abstract][Full Text] [Related]
27. Prescribing or deprescribing in older persons: what are the real‑life concerns in geriatric practice?
Bień B; Bień-Barkowska K
Pol Arch Intern Med; 2018 Apr; 128(4):200-208. PubMed ID: 29442099
[TBL] [Abstract][Full Text] [Related]
28. Barricades and brickwalls--a qualitative study exploring perceptions of medication use and deprescribing in long-term care.
Palagyi A; Keay L; Harper J; Potter J; Lindley RI
BMC Geriatr; 2016 Jan; 16():15. PubMed ID: 26767619
[TBL] [Abstract][Full Text] [Related]
29. Nursing home team-care deprescribing study: a stepped-wedge randomised controlled trial protocol.
Kua CH; Yeo CYY; Char CWT; Tan CWY; Tan PC; Mak VS; Lee SWH; Leong IY
BMJ Open; 2017 May; 7(5):e015293. PubMed ID: 28490560
[TBL] [Abstract][Full Text] [Related]
30. [Important aspects of geriatric pharmacotherapy].
Borchelt M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):593-8. PubMed ID: 15887071
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of elderly patients with polypharmacy who refuse to participate in an in-hospital deprescribing intervention: a retrospective cross-sectional study.
Komagamine J; Sugawara K; Hagane K
BMC Geriatr; 2018 Apr; 18(1):96. PubMed ID: 29665778
[TBL] [Abstract][Full Text] [Related]
32. Cooperation between geriatricians and general practitioners for improved pharmacotherapy in home-dwelling elderly people receiving polypharmacy - the COOP Study: study protocol for a cluster randomised controlled trial.
Romskaug R; Molden E; Straand J; Kersten H; Skovlund E; Pitkala KH; Wyller TB
Trials; 2017 Apr; 18(1):158. PubMed ID: 28372591
[TBL] [Abstract][Full Text] [Related]
33. Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strategies).
Fialová D; Laffon B; Marinković V; Tasić L; Doro P; Sόos G; Mota J; Dogan S; Brkić J; Teixeira JP; Valdiglesias V; Costa S;
Eur J Clin Pharmacol; 2019 Apr; 75(4):451-466. PubMed ID: 30610276
[TBL] [Abstract][Full Text] [Related]
34. Deprescribing: a new goal focused on the patient.
Machado-Alba JE; Gaviria-Mendoza A; Machado-Duque ME; Chica L
Expert Opin Drug Saf; 2017 Feb; 16(2):111-112. PubMed ID: 27984921
[TBL] [Abstract][Full Text] [Related]
35. Deprescribing Tool for Older PeoPle with Limited-life Expectancy (De-TOPPLE) version 1: Development and validation using a modified Delphi technique.
Shrestha S; Poudel A; Steadman KJ; Nissen LM
Basic Clin Pharmacol Toxicol; 2024 Jan; 134(1):15-27. PubMed ID: 37264733
[TBL] [Abstract][Full Text] [Related]
36. [Not Available].
Wehling M
Drug Res (Stuttg); 2019 Nov; 69(S 01):S16-S18. PubMed ID: 31731305
[No Abstract] [Full Text] [Related]
37. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals.
Turner JP; Edwards S; Stanners M; Shakib S; Bell JS
BMJ Open; 2016 Mar; 6(3):e009781. PubMed ID: 26966056
[TBL] [Abstract][Full Text] [Related]
38. What influences prescribing decisions in a multimorbidity and polypharmacy context on the acute medical unit? An interprofessional, qualitative study.
Rivers PH; Langford N; Whitehead A; Harrison T
J Eval Clin Pract; 2021 Oct; 27(5):1076-1084. PubMed ID: 33314589
[TBL] [Abstract][Full Text] [Related]
39. STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy): consensus validation.
Lavan AH; Gallagher P; Parsons C; O'Mahony D
Age Ageing; 2017 Jul; 46(4):600-607. PubMed ID: 28119312
[TBL] [Abstract][Full Text] [Related]
40. Frailty, polypharmacy and deprescribing.
Drug Ther Bull; 2016 Jun; 54(6):69-72. PubMed ID: 27284125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
